

**The listing of claims presented below replaces all prior versions and listing of claims in the application.**

**Listing of claims:**

1. (Withdrawn) A method for the treatment of an individual having a condition characterized by abnormal myocardial cell  $\text{Na}^+$ ,  $\text{K}^+$  or  $\text{Ca}^{2+}$  ion levels, said method comprising administering a therapeutically effective amount of one or more ~~ss; 3~~  $\beta_3$  adrenoceptor agonists to said individual.
2. (Withdrawn) The method according to claim 1 wherein the condition is selected from the group consisting of heart failure, and myocardial hypertrophy.
3. (Currently amended) A method for the treatment of a human ~~an individual~~ suffering from or susceptible to heart failure or myocardial hypertrophy, said method comprising administering a therapeutically effective amount of one or more  $\beta_3$  adrenoceptor agonists to said human ~~an individual~~.
4. (Currently amended) The method according to claim 3 wherein the human has ~~individual is an individual having~~ one or more clinical symptoms of heart failure or myocardial hypertrophy.
5. (Previously presented) The method according to claim 3 wherein the  $\beta_3$ - adrenoceptor agonist is selected from the group consisting of aryethanolamines, aryloxypropanolamines, and trimetoquinols.
6. (Previously presented) The method according to claim 3 wherein the  $\beta_3$  adrenoceptor agonist is selected from the group consisting of BRL37344, BRL 26830, BRL 26830A, BRL 35113, ZD7114, CGP12177, CGP 12177A, CGP-20712A, CL316243, ICI07114, ICI215001, ICI 201651, BRL35135A, BRL28410, N-5984, (R)-N-[4-[2-[[2-Hydroxy-2- (pyridin-3-yl)ethyl]amino]ethyl]phenyl]- 4- [4-(4-trifluoro-methylphenyl)thiazol-2- yl] benzenesulfonamide (L-796568), (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)- ethyl]amino]ethyl]phenyl]-1-(4-octylthiazol-2-

yl)-5-indolinesulfonamide (L-755507), L- 770,644, L-766,892, L-757,793, L-796568, LY-377604, Ro 40-2148, SB-220646, SB- 226552, SB-251023, SB-262552, SR 58306, SR 58375, SR 58339, SR 58611, SR 58611A, SR 59119A, GR-265261-X, AD-9677, and agonists of the series 2-(3-indolyl) alkylamino-1-(3-chlorophenyl)ethanols.

7. (Original) The method according to claim 3 wherein the  $\beta_3$  adrenoceptor agonist is BRL37344.
8. (Currently amended) The method according to claim 3 wherein the  $\beta_3$ -adrenoceptor agonist further comprises  $\beta_1$  antagonist activity ~~and-or~~ and/or further comprises ~~ss, 2~~  $\beta_2$  antagonist activity.
9. (Currently amended) The method according to claim 3 further comprising administering one or more  $\beta$  blockers to said human individual.
10. (Original) The method according to claim 9 wherein the  $\beta$  blocker is nadolol.
11. (Original) The method according to claim 9 wherein the  $\beta$  blocker is a  $\beta_1$  and/or  $\beta_2$  adrenoceptor antagonist.
12. (Currently amended) The method according to claim 9 wherein the  $\beta$  blocker is administered to said human individual prior to, simultaneously with or subsequent to administration of the one or more  $\beta_3$  adrenoceptor agonists.
13. (Currently amended) The method according to claim 3 wherein said human is suffering from chronic heart failure and further comprising at least partially stabilizing said human individual prior to administration of said  $\beta_3$  adrenoceptor agonist.
14. (Original) The method according to claim 13 wherein said stabilizing comprises treatment with one or more compounds selected from the group consisting of ACE- inhibitors, aldosterone antagonists and  $\beta$ -adrenoceptor antagonists.

15. (Withdrawn) A method for treatment of a condition characterized by abnormally high myocardial cell Na<sup>+</sup> ion level, said method comprising administration to an individual having said condition of a therapeutically effective amount of one or more  $\beta_3$ - adrenoceptor agonists.
16. (Withdrawn) The method according to claim 15 wherein said condition characterized by abnormally high myocardial cell Na<sup>+</sup> ion level is selected from the group consisting of heart failure, myocardial hypertrophy, and diabetic cardiomyopathy.
17. (Withdrawn) Use of one or more  $\beta_3$  adrenoceptor agonists for the manufacture of a medicament for treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels.
18. (Withdrawn) One or more  $\beta_3$ -adrenoceptor agonists for use in the treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels.
19. (Withdrawn) Use of one or more  $\beta_3$ -adrenoceptor agonists for the manufacture of a medicament for treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy.
20. (Withdrawn) One or more  $\beta_3$ -adrenoceptor agonists for use in the treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy.
21. (Withdrawn) A pharmaceutical composition for use in the treatment of an individual having a condition characterized by abnormal myocardial cell Na<sup>+</sup>, K<sup>+</sup> or Ca<sup>2+</sup> ion levels, the composition comprising one or more  $\beta_3$  adrenoceptor agonists together with one or more pharmaceutically acceptable adjuvants, excipients and/or carriers.
22. (Withdrawn) A pharmaceutical composition for use in the treatment of an individual suffering from or susceptible to heart failure or myocardial hypertrophy, the composition comprising one or more  $\beta_3$  adrenoceptor agonists together with one or more pharmaceutically acceptable adjuvants,

excipients and/or carriers.

23. (Withdrawn) A pharmaceutical composition comprising one or more  $\beta_3$  adrenoceptor agonists and one or more  $\beta_1$  and/or  $\beta_2$  adrenoceptor antagonists, together with one or more pharmaceutically acceptable adjuvants, excipients and/or carriers.

24. (Withdrawn) A method for the extrusion of  $\text{Na}^+$  from a myocardial cell or cells, the method comprising contacting said cell (s) one or more  $\beta_3$  adrenoceptor agonist(s).

25. (Withdrawn) The method according to claim 24 wherein said method comprises Na,K pump stimulation.